Jiangsu Yabang Johnson & Johnson Pharmaceutical Co., Ltd.

To evaluate the efficacy and safety of clotrimazole lozenges in the treatment of oropharyngeal candidiasis.

The purpose of this study is to use indapamide tablets (specification: 2.5 mg) provided by Jiangsu Yabang Johnson Pharmaceutical Co., Ltd. as the test preparation and indapamide tablets (trade name: Natrilix® specification: 2.5 mg) produced by Servier Pharmaceuticals in France as the reference preparation, and to evaluate the bioequivalence of the two in healthy subjects in the fasting state in accordance with the relevant provisions of the bioequivalence test.

The purpose of this study is to use Moxifloxacin Hydrochloride Tablets developed by Jiangsu Yabang Johnson Pharmaceutical Co., Ltd. as the test preparation and Moxifloxacin Hydrochloride Tablets (trade name: Bayfule) produced by Bayer HealthCare Co., Ltd. as the reference preparation. According to the relevant provisions of bioequivalence tests, the human bioavailability and bioequivalence tests are carried out on an empty stomach and after a high-fat diet, the relative bioavailability of the test preparation is calculated, and the bioequivalence of the two preparations is evaluated.